India leads on non-animal testing and its draft lab animal rules threaten to undo that

Using animal biology to model human disease has long reached its scientific and moral limits. Worldwide, progressive regulators are replacing animal experimentation with human-relevant methods that deliver faster, more reliable safety data. But India is poised to weaken statutory protections and lower ethical standards it has, ironically, demonstrated leadership in.

At the centre of this regressive shift is the draft Prevention of Cruelty to Animals (Control and Supervision of Experiments, Breeding and Trading of Laboratory Animals) Rules 2026. Issued by Committee for Control and Supervision of Experiments on Animals (CCSEA) under fisheries, animal husbandry and dairying ministry, the proposed text seeks to replace foundational frameworks established in 1968 and 1998.

Also read: Experiments on animals set to become easier


While proponents argue the draft streamlines approvals for research institutions and pharma companies, animal rights groups and NALSAR University of Law, Hyderabad, warn that the proposed rules are bad in law, regressive for science, fall short of ethical guidelines, and are profoundly short-sighted.

'Severe suffering' made ok

Draft rules permit experiments involving 'severe suffering'. This includes prolonged social isolation of dogs and primates, electric shocks, extreme movement restriction, lethal chemotherapy and fatal toxicity testing.

While Rule 7(2) purports to prohibit unalleviable severe pain over long periods, the rules fail to explain how permitted procedures will be reconciled against that prohibition. Also, the draft lacks enforceable criteria to resolve conflicts of interest, or independent pre-study review before such high-severity work begins.

Decentralisation of approvals

Under the draft, local institutional animal ethics committees (IAECs) gain authority to approve mild and moderate experiments on larger animals - dogs, cattle, pigs, etc - without prior central CCSEA clearance. Severe and non-recovery experiments involving animals beyond rodents and lagomorphs would still require central approval following IAEC recommendations. But post-hoc reporting is no substitute for prior independent scrutiny.

Weak oversight

Protections for wild, community and stray animals - including species protected under CITES and Wildlife Protection Act 1972 - are severely compromised. By introducing conditional exemptions for free-roaming and feral animals, the draft rolls back long-standing bans on experimenting on wild populations.

Also, IAECs can now permit sourcing livestock from open markets or unregistered suppliers. In a country already struggling with stray animal mismanagement and illegal wildlife trafficking, diluting procurement oversight not only exposes vulnerable animals to systemic abuse, but also compromises scientific rigour due to high biological variability.

What about the parent law?

The draft is inconsistent with the parent law - Prevention of Cruelty to Animals (PCA) Act 1960 - particularly Section 17 regarding CCSEA's statutory duties and rulemaking powers, thereby violating safeguards already entrenched in Indian law.

Flouting court guidelines

The draft rules violate principles laid down in Supreme Court's 'Animal Welfare Board of India v. A Nagaraja & Ors' (2014) verdict that read the 'Five Freedoms' of animals and their right to live with dignity into Section 3 (duty of care) and Section 11 (cruelty offences) of PCA Act.

While the draft explicitly invokes the internationally recognised 3Rs - replacement, reduction, refinement - it creates a glaring policy paradox. In principle, replacement obligates researchers to actively pursue non-animal methods wherever scientifically satisfactory alternatives exist, using live animals only as a last resort.

In practice, though, by decentralising approvals, softening restrictions, and broadening exemptions for wild and stray animals, the proposed framework makes it cheaper, faster and easier to experiment on live animals - reducing the 3Rs to mere declarations of intent.

Global regulatory bodies have recognised the imperative to transition away from outdated models. In the US, FDA Modernisation Act 2.0 (Dec 2022) removed statutory requirements for animal testing before human clinical trials, establishing a clear pathway for human-relevant alternative methods.

Also read: The Secret Social Lives of Animals Are Finally Being Decoded, and AI Is the Reason Why

The EU legally mandates strict application of the 3Rs wherever scientifically possible, while Britain invests heavily in advanced alternatives through National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). OECD routinely updates its Mutual Acceptance of Data framework to formally incorporate validated non-animal methods into international chemical safety guidelines.

The scientific case for change is compelling. Species differences limit how reliably animal studies predict human responses. Over 90% of drug candidates that appear safe in animal trials fail in human clinical trials. New approach methodologies (NAMs) replace imprecise disease-specific animal models with direct human biology, bypassing multi-stage animal trials, and delivering faster, decisive safety data.

Policy frameworks must actively incentivise development and integration of NAMs - organ-on-a-chip systems, 3D organoids, validated models like EpiDerm, etc - by formalising regulatory acceptance, establishing standardised validation protocols and directing funding toward human-relevant technologies.

India has previously demonstrated leadership by banning animal testing for cosmetics and explicitly recognising non-animal approaches in the 2023 amendment to New Drugs and Clinical Trials Rules. True regulatory reform requires dismantling anthropocentric lawmaking in favour of frameworks that value non-human life and scientific accuracy. India must build on its progress, reject retrograde rules, and realign its legal policy with modern, human-relevant research.

kumkum.dasgupta@timesofindia.com